Figure 1.

Characterization of a ligand-dependent and -independent SSTR3 phenotype in GC transfectants. A and B, SRIF-14 efficacy (A) and potency (B) in GpSSTR3^WT and GpCon cotreated with 3-isobutyl-1-methylxanthine and 1 μM forskolin (FOR, Sigma-Aldrich) in DMEM supplemented with 0.3% BSA for 30 minutes, representative of 3 repeated experiments. C, Relative expression of endogenous rSstr2 and hSSTR3 transgene in untreated GpSSTR3^WT and GpCon (n = 4). N.D., not detected. D, baseline rGH mRNA expression normalized to β-actin measured at 48 hours after plating (n = 5). E, GH levels measured in the medium of GpSSTR3^WT and GpCon at 48 hours after plating normalized to WST-1 absorbance (n = 4). **, P < .01.